HealthcareServices

Atrial Septal Defect Market 2026–2030: Forecasting Business Opportunities Ahead

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the atrial septal defect market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Atrial Septal Defect Market show for the 2026–2030 period?

The atrial septal defect market has shown significant growth over recent years. It is anticipated to expand from $4.46 billion in 2025 to $4.81 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.8%. This historical expansion can be attributed to several factors, including enhanced detection of congenital heart defects, greater availability of surgical correction methods, the expansion of pediatric cardiology services, increasing clinical experience with device-based closures, and broader access to diagnostic imaging technologies.

The atrial septal defect market is anticipated to experience substantial growth in the coming years. It is projected to reach $6.26 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. The expansion during this period can be attributed to the increasing adoption of hybrid closure techniques, a rising focus on early intervention in adults, the broadening of minimally invasive cardiac surgery capabilities, ongoing innovation in occluder device design, and a growing demand for long-term follow-up care solutions. Key trends expected over the forecast period include the increasing adoption of transcatheter closure devices, a growing preference for minimally invasive repair procedures, expanded use of advanced cardiac imaging techniques, the widening of pediatric and adult asd screening programs, and an enhanced emphasis on long-term patient outcomes.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16345&type=smp

What Drivers Are Shaping The Development Of The Atrial Septal Defect Market?

The rising occurrence of congenital heart defects (CHD) is anticipated to fuel the expansion of the atrial septal defect market in the future. Congenital heart defects are defined as structural irregularities within the heart that are present from birth. This increasing prevalence signifies a growing count of individuals identified with these structural heart abnormalities from birth. Treatment for atrial septal defects aids in addressing congenital heart defects by correcting unusual blood flow between the heart’s internal chambers, thus enhancing overall cardiac function and diminishing related complications. For example, as of September 2025, the British Heart Foundation, a non-profit organization based in the UK, reported that 2.3 million people in the UK are currently living with congenital heart disease. Moreover, congenital heart disease defects are identified in at least 1 in 150 births, which translates to an average of 13 babies daily in the UK, with additional diagnoses occurring later in life. Projections indicate that up to 1-2 percent of the population could be affected. Consequently, the widespread prevalence of congenital heart defects will propel the atrial septal defect market.

Which Segments Are Contributing To The Growth Of The Atrial Septal Defect Market?

The atrial septal defect market covered in this report is segmented –

1) By Treatment Procedure: Surgical Closure, Transcatheter Closure, Hybrid Procedures, Medication Therapy

2) By Diagnosis: Chest X-Ray, Electrocardiogram, Cardiac Catheterization, Transesophageal Echocardiography, Pulse Oximetry

3) By Product Type: Medical Devices, Pharmaceutical Products

4) By Age Group: Pediatric, Adult

5) By End-User: Hospitals, Ambulatory Surgical Centers, Cardiac Clinics, Other End-Users

Subsegments:

1) By Surgical Closure: Open Heart Surgery (Traditional Surgical Closure), Minimally Invasive Surgical Closure, Patches (Pericardial, Synthetic) For Asd Closure

2) By Transcatheter Closure: Device-Based Closure (Amplatzer Septal Occluder), Transcatheter Plug Closure Techniques, Catheter-Based Asd Repair For Adult And Pediatric Patients

3) By Hybrid Procedures: Combination Of Surgical And Transcatheter Techniques, Minimally Invasive Hybrid Procedures, Hybrid Closure For Complex Or Large Asds

4) By Medication Therapy: Anticoagulant Therapy (To Prevent Stroke), Diuretics (For Managing Symptoms), Antihypertensive Drugs (For Managing Associated Conditions), Off-Label Use Of Other Medications

Which Innovation Trends Are Advancing Developments Within The Atrial Septal Defect Market?

Leading companies in the arterial septal defect market are developing advanced devices and pursuing approval to expand their availability and uses. Device approval involves obtaining official authorization or certification for a device, typically from a regulatory body or relevant authority, before its legal manufacture, sale, or usage in a specific market or for a particular purpose. For instance, in March 2024, Occlutech GmbH, a Sweden-based specialist provider of minimally invasive cardiac devices, announced that the United States Food and Drug Administration (FDA) had approved the Occlutech ASD Occluder and Occlutech Pistol Pusher for addressing atrial septal defects (ASD). This authorization represents a significant achievement for the company, which has been committed to advancing global healthcare. The Occlutech ASD Occluder is engineered as a lifelong treatment for patients with echocardiography-confirmed defects. It is a self-expanding nitinol device comprising two flexible discs attached to both sides of the patient’s atrial septum using the Occlutech Pistol Pusher. With this approval, Occlutech will initiate commercialization in the US through an exclusive partnership with B. Braun Interventional Systems.

Who Are The Prominent Global Companies Shaping The Atrial Septal Defect Market Landscape?

Major companies operating in the atrial septal defect market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, W. L. Gore & Associates Inc., Cook Medical, Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Lifetech Scientific Corporation, Venus Medtech Hangzhou Inc, Occlutech Holding AG, Osypka AG, Cardia Inc, Gore Medical, Pfm Medical AG, Balton Sp. z o.o., Meril Life Sciences, TTK Healthcare, Braile Biomedica, Shanghai Shape Memory Alloy

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/atrial-septal-defect-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Atrial Septal Defect Market?

North America was the largest region in the atrial septal defect market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atrial septal defect market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Atrial Septal Defect Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16345&type=smp

Browse Through More Reports Similar to the Global Atrial Septal Defect Market 2026, By The Business Research Company

Congenital Heart Defect Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/congenital-heart-defect-devices-global-market-report

Left Atrial Appendage Closure Device Market Report 2026

https://www.thebusinessresearchcompany.com/report/left-atrial-appendage-closure-device-global-market-report

Atrial Fibrillation Market Report 2026

https://www.thebusinessresearchcompany.com/report/atrial-fibrillation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795